News coverage about Impax Laboratories (NASDAQ:IPXL) has trended somewhat positive recently, Accern reports. Accern scores the sentiment of media coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Impax Laboratories earned a media sentiment score of 0.22 on Accern’s scale. Accern also gave news stories about the specialty pharmaceutical company an impact score of 45.075030464816 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
IPXL has been the topic of several research reports. Canaccord Genuity set a $19.00 target price on Impax Laboratories and gave the company a “hold” rating in a research report on Monday, December 18th. Cantor Fitzgerald reaffirmed a “buy” rating and set a $25.00 target price on shares of Impax Laboratories in a research report on Monday, September 25th. Guggenheim began coverage on Impax Laboratories in a research report on Tuesday, December 12th. They set a “neutral” rating and a $18.00 target price on the stock. BTIG Research reissued a “buy” rating and issued a $27.00 price objective (up previously from $20.00) on shares of Impax Laboratories in a research report on Saturday, September 23rd. Finally, Zacks Investment Research raised Impax Laboratories from a “hold” rating to a “buy” rating and set a $23.00 price objective for the company in a research report on Monday, October 16th. Four equities research analysts have rated the stock with a sell rating, nine have assigned a hold rating and five have issued a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus target price of $19.62.
Impax Laboratories (NASDAQ IPXL) traded up $0.60 during midday trading on Friday, hitting $19.10. The company’s stock had a trading volume of 727,105 shares, compared to its average volume of 906,359. The stock has a market cap of $1,420.00, a price-to-earnings ratio of -3.06, a P/E/G ratio of 0.98 and a beta of 0.94. Impax Laboratories has a twelve month low of $7.75 and a twelve month high of $25.70. The company has a debt-to-equity ratio of 1.59, a current ratio of 1.81 and a quick ratio of 1.32.
Impax Laboratories (NASDAQ:IPXL) last announced its quarterly earnings results on Thursday, November 9th. The specialty pharmaceutical company reported $0.23 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.20 by $0.03. Impax Laboratories had a positive return on equity of 9.06% and a negative net margin of 56.59%. The firm had revenue of $206.40 million during the quarter, compared to analyst estimates of $208.38 million. During the same quarter in the previous year, the business earned $0.37 EPS. Impax Laboratories’s revenue for the quarter was down 9.4% compared to the same quarter last year. sell-side analysts expect that Impax Laboratories will post 0.64 earnings per share for the current year.
ILLEGAL ACTIVITY NOTICE: “Somewhat Positive Press Coverage Somewhat Unlikely to Affect Impax Laboratories (IPXL) Stock Price” was first posted by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are accessing this report on another website, it was stolen and reposted in violation of US & international copyright laws. The legal version of this report can be viewed at https://www.thelincolnianonline.com/2018/01/13/impax-laboratories-ipxl-earns-daily-news-sentiment-rating-of-0-22-updated-updated.html.
About Impax Laboratories
Impax Laboratories, Inc is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and marketing of bioequivalent pharmaceutical products (generics), in addition to the development and marketing of branded products. Its segments include Impax Generics and Impax Specialty Pharma.
Receive News & Ratings for Impax Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Impax Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.